AG
AGIO icon

Artal Group’s Agios Pharmaceuticals AGIO Stock Holding History

Artal Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-376,000
Closed -$20.1M – 135
2020
Q2 		$20.1M Sell
376,000
-24,000
-6% -$1.11M 0.56% 41
2020
Q1 		$14.2M Sell
400,000
-200,000
-33% -$9.24M 0.6% 37
2019
Q4 		$28.6M Buy
600,000
+200,000
+50% +$7.56M 1.11% 20
2019
Q3 		$13M Sell
400,000
-100,000
-20% -$4.14M 0.52% 39
2019
Q2 		$24.9M Buy
500,000
+100,000
+25% +$5.34M 1.01% 23
2019
Q1 		$27M Hold
400,000
– – 1.1% 24
2018
Q4 		$18.4M Buy
400,000
+100,000
+33% +$6.17M 0.68% 29
2018
Q3 		$23.1M Sell
300,000
-50,000
-14% -$4.02M 0.6% 25
2018
Q2 		$29.5M Sell
350,000
-150,000
-30% -$13.1M 0.63% 21
2018
Q1 		$40.9M Hold
500,000
– – 0.51% 21
2017
Q4 		$28.6M Buy
500,000
+50,000
+11% +$3.15M 0.43% 21
2017
Q3 		$30M Sell
450,000
-250,000
-36% -$15M 0.52% 10
2017
Q2 		$36M Sell
700,000
-50,000
-7% -$2.56M 0.63% 13
2017
Q1 		$43.8M Hold
750,000
– – 0.97% 9
2016
Q4 		$31.3M Buy
750,000
+350,000
+88% +$18.4M 0.69% 17
2016
Q3 		$21.1M Buy
400,000
+25,000
+7% +$1.09M 0.42% 24
2016
Q2 		$15.7M Buy
375,000
+40,000
+12% +$1.98M 0.32% 24
2016
Q1 		$13.6M Buy
335,000
+60,000
+22% +$2.57M 0.27% 26
2015
Q4 		$17.9M Buy
275,000
+50,000
+22% +$3.28M 0.34% 35
2015
Q3 		$15.9M Buy
225,000
+65,000
+41% +$6.35M 0.35% 39
2015
Q2 		$17.8M Buy
160,000
+20,000
+14% +$2.15M 0.77% 36
2015
Q1 		$13.2M Buy
140,000
+50,000
+56% +$5.6M 0.61% 40
2014
Q4 		$10.1M Sell
90,000
-100,000
-53% -$8.93M 0.35% 47
2014
Q3 		$11.7M Buy
190,000
+15,000
+9% +$647K 0.43% 41
2014
Q2 		$8.02M Buy
175,000
+75,000
+75% +$3.06M 0.32% 56
2014
Q1 		$3.92M Sell
100,000
-10,000
-9% -$335K 0.14% 77
2013
Q4 		$2.63M Buy
110,000
+40,000
+57% +$912K 0.09% 75
2013
Q3 		$1.96M Buy
+70,000
New +$1.93M 0.06% 74

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group's AGIO Position: Q3 2020 in Review

Artal Group sold out of Agios Pharmaceuticals (AGIO) in Q3 2020, closing a stake of 376,000 shares — an estimated $20.1M sold.

Artal Group first reported a position in AGIO in Q3 2013 and held it in 28 quarters. The position peaked at $43.8M in Q1 2017. 214 funds tracked by Wall St. Rank hold AGIO as of Q3 2020.

  • Artal Group reported no remaining Agios Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Artal Group sold 376,000 Agios Pharmaceuticals shares in Q3 2020, an estimated $20.1M.
  • Artal Group first reported a position in Agios Pharmaceuticals in Q3 2013 and held it in 28 quarters.
  • Artal Group's Agios Pharmaceuticals position peaked at $43.8M in Q1 2017.
  • 214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2020.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.